STOCK TITAN

CV Form 4: Director Hui Ying Kuo Receives 2,887 RSUs Scheduled to Vest

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

CapsoVision, Inc. (CV) director Hui Ying Kuo received 2,887 Restricted Stock Units (RSUs) in a non‑derivative issuance dated 09/15/2025. Each RSU represents the contingent right to one share of common stock, and the RSUs are scheduled to vest on 12/31/2025. Following the reported grant the reporting person beneficially owns 2,887 shares on a direct basis at a $0 per‑share issuance price. The Form 4 was filed to disclose this issuance under Section 16 reporting rules; no options, dispositions, or other classes of securities are reported on this form.

Positive

  • Grant aligns director incentives with shareholders via RSUs converting to common stock on vesting
  • Clear vesting schedule: RSUs scheduled to vest on 12/31/2025, providing transparency on timing of potential share issuance
  • Direct beneficial ownership disclosed: 2,887 shares reported as directly beneficially owned following the grant

Negative

  • None.

Insights

TL;DR: Director received RSUs that align personal compensation with shareholder outcomes without immediate dilution.

The grant of 2,887 RSUs to a director is a routine equity compensation mechanism to align long‑term interests with shareholders. These RSUs are contingent rights to receive common stock and vest on 12/31/2025, creating a retention incentive through year end. The issuance price is recorded as $0, indicating the award is compensation rather than a purchase. From a governance perspective this is customary for boards but should be reviewed relative to peer director compensation levels and potential future dilution once vested shares are delivered.

TL;DR: The transaction is a compensation grant with limited immediate market impact; monitor eventual share delivery.

Reporting shows a single non‑derivative award of 2,887 RSUs converting one‑for‑one into common shares upon vesting. There is no cash consideration reported and no sale or exercise activity. Absent additional material awards or dispositions, this Form 4 alone is unlikely to move valuation materially, though investors may note timing of vesting and potential future share issuance when assessing share count and dilution.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
1. Name and Address of Reporting Person*
Kuo Hui Ying

(Last) (First) (Middle)
C/O CAPSOVISION, INC.
18805 COX AVENUE, SUITE 250

(Street)
SARATOGA CA 95070

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
CapsoVision, Inc [ CV ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
Officer (give title below) Other (specify below)
3. Date of Earliest Transaction (Month/Day/Year)
09/15/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Restricted Stock Unit (RSU) (1) 09/15/2025 A 2,887 (2) (2) Common Stock 2,887 $0 2,887 D
Explanation of Responses:
1. Each Restricted Stock Unit (the "RSU") represents a contingent right to receive one share of the Issuer's common stock.
2. These RSUs are scheduled to vest on December 31, 2025
Remarks:
/s/ Kang-Huai (Johnny) Wang, Attorney-in-Fact for Hui Ying Kuo 09/17/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did CapsoVision (CV) disclose on this Form 4?

The Form 4 discloses a grant of 2,887 Restricted Stock Units (RSUs) to director Hui Ying Kuo dated 09/15/2025, each RSU representing one share and scheduled to vest on 12/31/2025.

How many shares will the 2,887 RSUs convert into for CV?

Each RSU represents a contingent right to one share of common stock, so the award is scheduled to convert into 2,887 shares upon vesting.

Was there any cash price paid for the RSUs reported for CV?

No cash consideration is reported; the RSUs are shown with a $0 issuance price, indicating a compensation grant rather than a purchase.

When do the awarded RSUs for CV vest?

The RSUs are scheduled to vest on 12/31/2025 according to the filing.

Does the Form 4 show any dispositions or exercises for CV insider Hui Ying Kuo?

No. The filing reports an acquisition of RSUs only; there are no reported dispositions, exercises, or other classes of transactions on this form.
CapsoVision, Inc.

NASDAQ:CV

CV Rankings

CV Latest News

CV Latest SEC Filings

CV Stock Data

283.40M
27.71M
40.69%
0.05%
Medical Devices
Electromedical & Electrotherapeutic Apparatus
Link
United States
SARATOGA